WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Blood

• Publication date

  2008-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2008-03-143735PMID 18497321
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

  2008cited by this paper
• Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.

  2007cited by this paper
• Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem-cell transplantation.

  2007cited by this paper
• Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation.

  2007cited by this paper
• Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

  2006cited by this paper
• Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantati

  2006cited by this paper
• Predicting survival and leukemic evolution in patients with myelodysplastic syndrome.

  2006cited by this paper
• Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.

  2006cited by this paper
• Myelodysplastic syndromes--coping with ineffective hematopoiesis.

  2005cited by this paper
• Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

  2005cited by this paper
• Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors.

  2004cited by this paper
• The WHO classification of MDS does make a difference.

  2004cited by this paper
• Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

  2004cited by this paper
• Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes

  2003cited by this paper
• Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia.

  2003cited by this paper
• Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.

  2002cited by this paper
• Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia.

  2002cited by this paper
• The World Health Organization (WHO) classification of the myeloid neoplasms.

  2002cited by this paper
• Haematopoietic stem cell transplantation for patients with myelo‐dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

  2000cited by this paper
• Report of an international working group to standardize response criteria for myelodysplastic syndromes.

  2000cited by this paper
• Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age.

  2000cited by this paper
• Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation.

  1998cited by this paper
• Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score.

  1998cited by this paper
• Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of different entities with 11q23 breakpoint

  1998cited by this paper
• International scoring system for evaluating prognosis in myelodysplastic syndromes.

  1997cited by this paper
• Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle.

  1996cited by this paper
• Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome.

  1993cited by this paper
• Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome.

  1990cited by this paper
• Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome.

  1990cited by this paper
• Bone marrow transplantation in patients with thalassemia.

  1990cited by this paper

• Risk stratification for survival and transformation into acute myeloid leukemia in patients with myelodysplastic syndrome based on the pathogenicity assessment of TP53 mutations

  2025cites this paper
• MSCs with upregulated lipid metabolism block hematopoietic stem cell differentiation via exosomal CTP-1A in MDS

  2025cites this paper
• Establishment of a machine learning-based prediction framework to assess trade-offs in decisions that affect post-HCT outcomes

  2025cites this paper
• Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome

  2025cites this paper
• SMARCA5 reprograms AKR1B1-mediated fructose metabolism to control leukemogenesis.

  2024cites this paper
• How we reduce and treat post-transplant relapse of MDS.

  2024cites this paper
• Iron chelation therapy

  2023cites this paper
• Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes

  2022cites this paper
• Transfusion dependence is a risk factor for severe infections in myelodysplastic syndromes.

  2022cites this paper
• Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia

  2022cites this paper
• BMT for Myelodysplastic Syndrome: When and Where and How

  2022cites this paper
• The genetics of myelodysplastic syndromes and the opportunities for tailored treatments

  2022cites this paper
• IPSS-R及WPSS移植前评估对异基因造血干细胞移植治疗骨髓增生异常综合征患者预后意义的研究

  2022cites this paper
• Senescent Mesenchymal Stem Cells in Myelodysplastic Syndrome: Functional Alterations, Molecular Mechanisms, and Therapeutic Strategies

  2021cites this paper
• Myelodysplastic syndrome and immunotherapy novel to next in-line treatments

  2021cites this paper
• Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome

  2021cites this paper
• Pre-transplant red blood cell and platelet transfusion burden in de novo myelodysplastic syndrome undergoing allogeneic transplantation: Pre-transplant red blood cell and platelet transfusion burden in de novo MDS after allogeneic transplantation.

  2021cites this paper
• Hematology, Transfusion and Cell Therapy 5-Azacytidine restores interleukin 6-increased production in mesenchymal stromal cells from myelodysplastic patients

  2021cites this paper
• Contemporary treatment approaches to CMML - Is allogeneic HCT the only cure?

  2020cites this paper
• Role of age and hematopoietic cell transplantation-specific comorbidity index in myelodysplastic patients undergoing an allotransplant. A retrospective study from the CMWP (Chronic Malignancies Working Party) of the EBMT.

  2020cites this paper
• 5-Azacytidine restores interleukin 6-increased production in mesenchymal stromal cells from myelodysplastic patients.

  2020cites this paper
• Indications for Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome

  2020cites this paper
• Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes

  2020cites this paper
• Prognostic Models in Myelodysplastic Syndromes

  2020cites this paper
• Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

  2020cites this paper
• Nationwide epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Japan: a multicenter retrospective study

  2020cites this paper
• Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome

  2020cites this paper
• Myelodysplastic syndromes: moving towards personalized management

  2020cites this paper
• Treatment of myelodysplastic syndrome in the era of next‐generation sequencing

  2019cites this paper
• Application of standard and novel prognostic systems in patients with myelodys- plastic syndrome undergoing allogeneic hematopoietic stem cell transplantation

  2019cites this paper
• Allogeneic stem cell transplant in myelodysplastic syndrome‐factors impacting survival

  2019cites this paper
• Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation

  2019cites this paper
• Respecting Cultural Differences in Goals of Care Conversations

  2019cites this paper
• [Myelodysplastic syndromes: recent advances in prognostic risk stratification systems].

  2019cites this paper
• A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation*

  2019cites this paper
• Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care

  2018cites this paper
• Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• the Radboud University Nijmegen

  2018cites this paper
• Pretransplantation: Indications and Timing

  2018cites this paper
• TP53 mutation in allogeneic hematopoietic cell transplantation for de novo myelodysplastic syndrome.

  2018cites this paper
• Comparison of transplant‐specific prognostic scoring systems in haploidentical transplantation for myelodysplastic syndrome

  2018cites this paper
• Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.

  2017influential citation
• Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

  2017cites this paper
• Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System

  2017cites this paper
• Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party

  2017cites this paper
• Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8.

  2017cites this paper
• Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes

  2017cites this paper
• Iron chelation therapy in low risk myelodysplastic syndrome

  2017cites this paper
• Haploidentical Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome.

  2017cites this paper
• Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.

  2017cites this paper
• The Myelodysplastic Syndromes and the Myelodysplastic/Myeloproliferative Neoplasms

  2017cites this paper
• Maximizing the benefit of allogeneic stem cell transplantation in myelodysplastic syndromes.

  2017cites this paper
• Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome

  2017cites this paper
• Association between Transfusion Status and Overall Survival in Patients with Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis

  2016cites this paper
• Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation.

  2016cites this paper
• Allogeneic : Adult Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome : A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT

  2016cites this paper
• Rainer Haas Myelodysplastic Syndromes : evaluation of different prognostic scores in patients treated with chemotherapy

  2016influential citation
• Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO)

  2016cites this paper
• Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter?

  2016cites this paper
• Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation

  2016cites this paper
• Causes of mortality after haploidentical hematopoietic stem cell transplantation and the comparison with HLA-identical sibling hematopoietic stem cell transplantation

  2016cites this paper
• Laboratory and clinical risk assessment to treat myelodysplatic syndromes

  2016cites this paper
• Prognostic factors in de novo myelodysplastic syndrome in young and middle-aged people

  2015cites this paper
• Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

  2015cites this paper
• Current state of prognostication and risk stratification in myelodysplastic syndromes

  2015cites this paper
• Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including allogeneic hematopoietic stem cell transplantation.

  2015cites this paper
• Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?

  2015cites this paper
• 地西他滨桥接异基因造血干细胞移植治疗骨髓增生异常综合征的疗效分析

  2015cites this paper
• Myelodysplastic Syndromes

  2015cites this paper
• [Retrospective efficacy analysis of decitabine bridging allogeneic hematopoietic stem cell transplantation on the treatment of myelodysplastic syndrome].

  2015cites this paper
• WPSS is a strong prognostic indicator for clinical outcome of allogeneic transplant for myelodysplastic syndrome in Southeast Asian patients

  2015cites this paper
• In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time

  2015cites this paper
• Transfusion, Iron, and Leukemogenesis: Implications for Myelodysplastic Syndrome

  2015cites this paper
• Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines

  2015cites this paper
• MDS prognostic scoring systems – past, present, and future.

  2015cites this paper
• Allogeneic hematopoietic cell transplantation in patients 60 to 70 years of age with de novo high-risk MDS or secondary AML – a comparison with patients lacking donors who received azacitidine Biol Blood Marrow Transplant

  2015cites this paper
• Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.

  2015cites this paper
• Transplant for MDS: challenges and emerging strategies.

  2015cites this paper
• Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.

  2015cites this paper
• Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome.

  2015cites this paper
• Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome

  2015cites this paper
• Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: lingering uncertainties and emerging possibilities.

  2015cites this paper
• Myelodysplastic syndromes, version 2.2015.

  2015cites this paper
• prognostic scoring systems – past, present, and future.

  2015cites this paper
• Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experience

  2014cites this paper
• Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes

  2014cites this paper
• Granulomatous Dermatitis Accompanied by Myelodysplastic Syndrome

  2014cites this paper
• Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy

  2014influential citation
• Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy.

  2014cites this paper
• Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.

  2014cites this paper
• Generalized granulomatous dermatitis accompanied by myelodysplastic syndrome.

  2014cites this paper
• Transplants in myelodysplastic syndromes.

  2014cites this paper
• Guidelines for the diagnosis and management of adult myelodysplastic syndromes

  2014cites this paper
• A comprehensive review of myelodysplastic syndrome patients with autoimmune diseases

  2014cites this paper
• Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes

  2014cites this paper
• Predictive factors for the outcome of allogeneic transplantation in patients with myelodysplastic syndrome stratified according to the revised International Prognostic scoring System (IPSS-R)

  2014cites this paper
• Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.

  2014cites this paper
• Prognostic assessment in myelodysplastic syndromes

  2014cites this paper
• Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes.

  2013cites this paper